Zofenopril Calcium Drug Asset Due Diligence Report 2026

This Zofenopril Calcium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Zofenopril Calcium can convert its Small molecule drug profile and ACE biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zofenopril Calcium (query alias: Zofenopril Calcium)
Modality / target	Small molecule drug; ACE; ACE inhibitors
Highest global status	Phase 2
Originator	Menarini International Operations Luxembourg SA
Active developers	Shanghai Institute of Pharmaceutical Industry, Jiangsu Kanion Pharmaceutical Co., Ltd.

The MCP disease footprint includes Essential Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05257148	Phase 4	Completed	283	Change in Mean Sitting DBP Between Week 0 (Visit 2) and Week 8 (Visit 3)
NCT05279807	Phase 4	Completed	277	Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)
NCT04254042	Phase 4	Completed	24	Change in nycthemeral blood pressure profile (mmHg)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Interventional Clinical Trial to Assess Efficacy and Safety of the Extemporaneous Combination of Zofenopril Calcium and Amlodipine in Grade 1-2 Hypertensive Patients Versus Each Monotherapy - (MASOLINO Study)

Phase 4; n=277; evaluation: not stated. Reported fields: Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)(Mean): Mean difference pre vs post treatment = -13.5(95% CI, -14.5 to -12.5), P-Value = < 0.001; Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)(Mean): Mean difference pre vs post treatment = -13.5(95% CI, -14.5 to -12.5), P-Value = < 0.001; Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)(Mean): Mean difference pre vs post treatment = -13.5(95% CI, -14.5 to -12.5), P-Value = < 0.001

Open-label, Multicenter, Multinational, Interventional Clinical Trial to Assess Effectiveness and SAfety of the Extemporaneous Combination of Nebivolol and Zofenopril Calcium in Grade 1 to 2 Hypertensive patIents Versus Each mOnotherapy

Phase 4; n=283; evaluation: not stated. Reported fields: Change in Mean Sitting DBP Between Week 0 (Visit 2) and Week 8 (Visit 3)(Mean): Mean Difference (Final Values) = -9.3, P-Value = <0.001; Change in Mean Sitting DBP Between Week 0 (Visit 2) and Week 8 (Visit 3)(Mean): Mean Difference (Final Values) = -9.3, P-Value = <0.001; Change in Mean Sitting DBP Between Week 0 (Visit 2) and Week 8 (Visit 3)(Mean) = -9.3 mmHg (Standard Deviation, 8.94)

PP.LB02.09 ZOFENOPRIL OR RAMIPRIL COMBINED WITH ASA IN THE EARLY TREATMENT OF ACUTE MYOCARDIAL INFARCTION ASSOCIATED WITH LEFT VENTRICULAR DYSFUNCTION. 5-YEAR FOLLOW-UP OF THE SMILE-4

Phase 3; n=265; evaluation: Positive. Reported fields: Cardiovascular hospitalization: OR = 0.61(95% CI, 0.37 - 0.99), P-Value = 0.047; Cardiovascular hospitalization: OR = 0.61(95% CI, 0.37 - 0.99), P-Value = 0.047

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zofenopril Calcium addresses Essential Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 8 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ACE records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2021-07-20	Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America	Approved	Financial terms not disclosed
	AstraZeneca divests rights to established hypertension medicines	Approved	US$350.0M upfront; US$40.0M milestones; US$390.0M stated total
2019-02-28	Adhera Therapeutics and Alyvant strike deal for Prestalia	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “New application of drug zofenopril calcium”. The milestone feed surfaced a patent-application signal described as “Dosage form with ace inhibitor”. The milestone feed surfaced a patent-application signal described as “Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO